SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (5932)11/12/1998 1:46:00 PM
From: Rocketman  Read Replies (1) of 9719
 
Sounds like Van Kasper is trying to bolster their recommendations, rather than accept reality. Sounds like an analyst caught with their pants down. Did they underwrite any of ENMD's funding by the way?

But, I can agree that with $38M in cash that ENMD has enough money to initiate clinical trials by themselves, just not enough to finish clinical trials by themselves. And a Phase 1 trial isn't going to resolve efficacy issues, just safety.

"The NCI delaying for a year" as stated in the article isn't backed up with a quote, but neither is this Van Kasper release.

You can bet that the FDA review of this data is going to be hit with a lot of controversy, and is not just going to be a slam dunk approval for proceeding with clinicals.

But, given the above and the Van Kasper damage control release I still think that ENMD is way overvalued.

Rman
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News